3H dendrimer nanoparticle organ/tumor distribution

Pharmaceutical Research

Volumn 21, Issue 3, 2004, Pages 476-483

  Nigavekar, Shraddha S ^a   Sung, Lok Yun ^a   Llanes, Mikel ^a   El Jawahri, Areej ^a   Lawrence, Theodore S ^a   Becker, Christopher W ^a   Balogh, Lajos ^b   Khan, Mohamed K ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Biodistribution; Melanoma; PAMAM dendrimers; Prostate cancer; Tritiated nanoparticles

Indexed keywords

ACETIC ANHYDRIDE; DENDRIMER; NANOPARTICLE; POLYAMIDOAMINE; POLYAMINE DERIVATIVE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG TISSUE LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; ANIMAL; EXPERIMENTAL MELANOMA; HUMAN; MELANOMA;

ANIMALS; DENDRIMERS; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; NANOPARTICLES; TISSUE DISTRIBUTION;

EID: 1542529996     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000019302.26097.cc     Document Type: Article

References (30)

1. L. Balogh, A. Bielinska, J. D. Eichman, R. Valluzzi, I. Lee, J. R. Baker, T. S. Lawrence, and M. K. Khan. Dendrimer nanocomposites in medicine. Chimica Oggi/Chemistry Today 20:35-40 (2002).
2. R. Esfand and D. A. Tomalia. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today 6:427-436 (2001).
3. J. F. G. A. Jansen, E. M. M. de Brabander-van den Berg, and E. W. Meijer. Encapsulation of guest molecules into a dendritic box. Science 266:1226-1229 (1994).
4. J. D. Eichman, A. U. Bielinska, J. F. Kukowska-Latallo, and J. R. Baker. The use of PAMAM dendrimers in the efficient transfer of genetic material into cells. Pharmaceutical Science and Technology Today 3:232-245 (2000).
5. J. F. Kukowska-Latallo, A. U. Bielinska, J. Johnson, R. Spindler, D. A. Tomalia, and J. R. Baker Jr. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc. Natl. Acad. Sci. U. S. A. 93:4897-4902 (1996).
6. A. Bielinska, J. F. Kukowska-Latallo, J. Johnson, D. A. Tomalia, and J. R. Baker Jr. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res. 24:2176-2182 (1996).
7. R. Delong, K. Stephenson, T. Loftus, M. Fisher, S. Alahari, A. Nolting, and R. L. Juliano. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J. Pharm. Sci. 86:762-764 (1997).
8. H. Yoo, P. Sazani, and R. L. Juliano. PAMAM dendrimers as delivery agents for antisense oligonucleotides. Pharm. Res. 16:1799-1804 (1999).
9. N. Malik, E. G. Evagorou, and R. Duncan. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 10:767-776 (1999).
10. B. Raduchel, H. Schmitt-Willich, J. Platzek, W. Ebert, T. Frenzel, B. Misselwitz, and H. J. Weinmann. Synthesis and characterization of novel dendrimer-based gadolinium complexes as MRI contrast agents for the vascular system. Proc. Amer. Chem. Soc. Polym. Mater. Sci. Eng. 79:516-517 (1998).
11. H. Kobayashi, N. Sato, S. Kawamoto, T. Saga, A. Hiraga, T. L. Haque, T. Ishimori, J. Konishi, K. Togashi, and M. W. Brechbiel. Comparison of the macromolecular MR contrast agents with ethylenediamine-core versus ammonia-core generation-6 polyamidoamine dendrimer. Bioconjug. Chem. 12:100-107 (2001).
12. L. P. Balogh, S. S. Nigavekar, A. C. Cook, L. Minc, and M. K. Khan. Development of dendrimer-gold radioactive nanocomposites to treat cancer microvasculature. PharmaChem 2:94-99 (2003).
13. 0-PAMAM} gold-dendrimer nanocomposites in cells. J. Nanoparticle Res. 4:395-403 (2002).
14. A. Quintana, E. Raczka, L. Piehler, I. Lee, A. Myc, I. Majoros, A. K. Patri, T. Thomas, J. Mule, and J. R. Baker Jr. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 19:1310-1316 (2002).
15. S. Shukla, G. Wu, M. Chatterjee, W. Yang, M. Sekido, L. A. Diop, and R. Muller. S. J. J., R. J. Lee, R. F. Barth, and W. Tjarks. Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjug. Chem. 14:158-167 (2003).
16. J. C. Roberts, M. K. Bhalgat, and R. T. Zera. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J. Biomed. Mater. Res. 30:53-65 (1996).
17. J. Peterson, V. Allikmaa, J. Subbi, T. Pehk, and M. Lopp. Structural deviations in poly(amidoamine) dendrimers: a MALDITOF MS analysis. European Polymer J. 39:33-42 (2003).
18. D. A. Tomalia, A. M. Naylor, and W. A. Goddard III. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angewandte Chemie International Edition English 29:138-175 (1990).
19. I. J. Majoros, B. Keszler, S. Wochler, T. Bull, and J. R. Baker Jr. Acetylation of poly(amidoamine) dendrimers. Macromolecules 36:5526-5529 (2003).
20. M. S. O'Reilly, L. Holmgren, Y. Shing, C. Chen, R. A. Rosenthal, M. Moses, W. S. Lane, Y. Cao, E. H. Sage, and J. Folkman. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328 (1994).
21. D. S. Wilbur, P. M. Pathare, D. K. Hamlin, K. R. Buhler, and R. L. Vessella. Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers. Bioconjug. Chem. 9:813-825 (1998).
22. C. Zhang, S. O'Brien, and L. Balogh. Comparison and Stability of CdSe Nanocrystals Covered with Amphiphilic Poly(Amidoamine) Dendrimers. J. Phys. Chem. B. 106:10316-10321 (2002).
23. J. Folkman. Tumor Angiogenesis. In J. F. Holland, R. C. Bast Jr., D. L. Morton, E. Frie III, D. W. Kufe, and R. R. Weichselbaum (eds.), Cancer Medicine, 4th edition, Williams and Wilkens, Baltimore, 1996, pp. 181-204.
24. J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:27-31 (1995).
25. H. Hashizume, P. Baluk, S. Morikawa, J. W. McLean, G. Thurston, S. Roberge, R. K. Jain, and D. M. McDonald. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol 156:1363-1380 (2000).
26. L. F. Brown, M. Detmar, K. Claffey, J. A. Nagy, D. Feng, A. M. Dvorak, and H. F. Dvorak. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 79:233-269 (1997).
27. T. W. Grunt, A. Lametschwandtner, and K. Karrer. The characteristic structural features of the blood vessels of the Lewis lung carcinoma (a light microscopic and scanning electron microscopic study). Scan. Electron Microsc. (Pt 2)2:575-89. (1986).
28. P. A. Stewart, K. Hayakawa, C. L. Farrell, and R. F. Del Maestro. Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect. J. Neurosurg. 67:697-705 (1987).
29. J. M. Brown and A. J. Giaccia. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58:1408-1416 (1998).
30. M. El-Sayed, M. F. Kiani, M. D. Naimark, A. H. Hikal, and H. Ghandehari. Extravasation of poly(amidoamine) (PAMAM) dendrimers across microvascular network endothelium. Pharm. Res. 18:23-28 (2001).